Back to search

Switzerland· 68793001

Paxlovid, Filmtabletten

A nirmatrelvir und ritonavir product containing nirmatrelvirum, ritonavirum, registered in Switzerland by Pfizer AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J05AE30

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedPaxlovid, FilmtablettenATCJ05AE30REGISTER NO.68793001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Nirmatrelvir und ritonavir is registered in 11 of 19 countries.

Countries holding a registration under ATC J05AE30 (nirmatrelvir und ritonavir), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Nirmatrelvir und ritonavir · ATC J05AE30

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nirmatrelvir und ritonavir costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.

  • Switzerland: $851.25 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Nirmatrelvir und ritonavir · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$851.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
nirmatrelvirum, ritonavirum
Manufacturer
Pfizer AG
Country
Switzerland (CH)
ATC code
J05AE30
ATC class
Nirmatrelvir und Ritonavir
Defined daily dose
0.6 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680687930017
    5 Blist 6 Stk
    CHF 1058.95

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for nirmatrelvir und ritonavir.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nirmatrelvir und ritonavir · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Nirmatrelvir und ritonavir in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nirmatrelvir und ritonavir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Paxlovid
  • Liechtenstein · Paxlovid
  • Norway · Paxlovid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ffc5b7da-080c-4c57-b633-0af20681c8e3
GET /v1/drugs/ffc5b7da-080c-4c57-b633-0af20681c8e3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "nirmatrelvirum 150 mg + ritonavirum 100 mg",
  "valid_from": "2026-03-01",
  "limitations": "[{\"description\":\"PAXLOVID wird als antivirale Monotherapie für die Behandlung einer bestätigten Covid-19 Infektion (Positiver Erregernachweis Antigen/PCR und vorhandener Covid-19-Symptome) in folgenden Fällen vergütet:<br>\\n&nbsp• in einer Dosierung von 300 mg Nirmatrelvir (zwei Tabletten zu je 150 mg) und 100 mg Ritonavir (eine Tablette zu 100 mg) zur gleichzeitigen Einnahme alle 12 Stunden, über einen Zeitraum von 5 Tagen<br>\\n&nbsp• zur Frühbehandlung (ausser bei immunsupprimierten Personen vorzugsweise innerhalb von 5 Tagen nach Symptombeginn) bei Erwachsenen, die keine Sauerstofftherapie oder Hospitalisierung aufgrund von COVID-19 benötigen und für welche gemäss der aktuell gültigen Kriterienliste der Schweizerischen Gesellschaft für Infektiologie (SSI) (https://www.sginf.ch/guidelines/guidelines-overview.html) ein erhöhtes Risiko für einen schweren COVID-19-Verlauf besteht.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21529.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-03-01\",\"validTo\":\"2029-02-28\"}]",
  "galenic_form": "Filmtabl 4x150 mg/2x100 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2023-12-01",
  "self_retention_pct": 10
}

See everything about nirmatrelvir und ritonavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.